Cyclin C – a novel therapeutic target for treating B-ALL

Cyclin C – a novel therapeutic target for treating B-ALL

Jana Trifinopoulos
NewsPapersResearch

Cyclin C – a novel therapeutic target for treating B-ALL

Despite significant therapeutic advancements in the treatment of acute lymphoblastic leukemia (ALL), challenges like drug resistance and long-term toxicities continue to hinder effective treatment. In a study led by Dagmar Gotthardt and Veronika Sexl, with support from the SFB and the Tissue Home program and esteemed international collaborators, first author Jana Trifinopoulos has identified cyclin C as a crucial factor in the development and maintenance of B-ALL. Importantly, while cyclin C is non-essential for normal hematopoiesis, its role in B-ALL suggests that targeting cyclin C could be a promising therapeutic strategy to increase cancer cell sensitivity to stress and chemotherapy.

Published in Haematologica

Jana Trifinopoulos, Julia List, Thorsten Klampfl, Klara Klein, Michaela Prchal-Murphy, Agnieszka Witalisz-Siepracka, Florian Bellutti, Luca L. Fava, Gerwin Heller, Sarah Stummer, Patricia Testori, Monique L. den Boer, Judith M. Boer, Sonja Marinovic, Gregor Hoermann, Wencke Walter, Andreas Villunger, Piotr Sicinski, Veronika Sexl, Dagmar Gotthardt

Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress response

https://haematologica.org/article/view/haematol.2024.285701

 © Jana Trifinopoulos